Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer recurring in patients who initially respond.

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently approved vaccine for TB – which recently surpassed COVID-19 to once again become the deadliest infectious disease on Earth – the findings are a great step forward in the quest to combat humanity’s ancient foe.

Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

"It's really exciting, because when we talk about curing cancer, it's not really a single monolithic disease," he added. "There are probably hundreds of different targets for ever

As per a new study, the potential of mRNA vaccines offers a personalized treatment for patients with pancreatic cancer.